Finance

Lists
Q2 2026 earnings • released • EPS beat +11.34% • Revenue beat +1.97%
See results
ALC:SWX
Alcon AG
CHF 60.68
+2.02%
(+1.20) 1D
Aug 14, 5:31:22 PM GMT+2  ·   CHF
All symbols
SymbolPriceChange% Change
Generating top insights for ALC...
Open
CHF 59.72
High
CHF 60.86
Low
CHF 59.72
Mkt. cap
30.34B
Avg. vol.
1.43M
Volume
1.29M
Dividend
0.46%
Quarterly dividend
CHF 0.07
Ex-dividend date
May 5, 2026
P/E ratio
57.23
52-wk high
CHF 72.88
52-wk low
CHF 47.80
EPS
CHF 1.06
Shares outstanding
499.70M
No. of employees
25K
Open
CHF 59.72
High
CHF 60.86
Low
CHF 59.72
Mkt. cap
30.34B
Avg. vol.
1.43M
Volume
1.29M
Dividend
0.46%
Quarterly dividend
CHF 0.07
Ex-dividend date
May 5, 2026
P/E ratio
57.23
52-wk high
CHF 72.88
52-wk low
CHF 47.80
EPS
CHF 1.06
Shares outstanding
499.70M
No. of employees
25K
News stories
From web sources and news partners
Profile
Alcon Inc. is a Swiss-American pharmaceutical and medical device company specializing in eye care products. Alcon is incorporated in the Canton of Fribourg, Switzerland, and its global headquarters are located in Geneva, but its main operational base is in Fort Worth, Texas, United States, where it employs about 4,500 people. Alcon was a subsidiary of Novartis until April 2019, when it was spun out into a separate publicly traded company. Alcon itself has a number of subsidiaries, including Aerie Pharmaceuticals, focused on therapies for glaucoma and other diseases of the eye, and WaveLight, which develops and manufactures laser eye surgery technologies. Wikipedia
About Alcon AG
CEODavid J. Endicott
Employees25K
Founded1945
HeadquartersGeneva, Geneva, Switzerland
SectorMedical device
Websitealcon.com
Last report
Aug 11, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$0.84 / $0.75
+11.34%beat
Revenue / Est. (USD)
2.82B / 2.77B
+1.97%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
2.60B
2.61B
2.72B
2.71B
Cost of goods sold
1.16B
1.16B
1.20B
1.14B
Cost of revenue
1.16B
1.16B
1.20B
1.14B
Research and development expenses
245.00M
248.00M
273.00M
245.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
870.00M
865.00M
901.00M
882.00M
Operating expense
1.14B
1.12B
1.20B
1.23B
Total operating expenses
2.31B
2.28B
2.40B
2.38B
Operating income
290.00M
336.00M
318.00M
330.00M
Other non operating income
-
3.00M
-28.00M
-
EBT including unusual items
199.00M
283.00M
264.00M
240.00M
EBT excluding unusual items
242.00M
287.00M
271.00M
278.00M
Income tax expense
23.00M
46.00M
47.00M
51.00M
Effective tax rate
11.56%
16.25%
17.80%
21.25%
Other operating expenses
26.00M
9.00M
26.00M
106.00M
Net income
176.00M
237.00M
217.00M
189.00M
Net profit margin
6.78%
9.07%
7.98%
6.98%
Earnings per share
0.76
0.79
0.78
0.85
Interest and investment income
4.00M
-
74.00M
2.00M
Interest expense
-51.00M
-51.00M
-53.00M
-52.00M
Net interest expenses
-47.00M
-51.00M
21.00M
-50.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
487.00M
784.00M
441.00M
600.00M
Gain or loss from assets sale
1.00M
5.00M
9.00M
2.00M
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps